Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020
December 07 2020 - 7:03AM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on discovering, acquiring,
developing and commercializing therapeutics in the disease areas of
immunology, inflammation and oncology, today announced that it will
host a conference call and webcast for investors and analysts on
Tuesday, December 15, 2020 at 11:00am ET to discuss GB002, its
inhaled PDGFR inhibitor, for the treatment of pulmonary arterial
hypertension (PAH).
This webcast will include a discussion of GB002’s development
program in PAH and initial results from the ongoing two-week Phase
1b clinical trial in patients, in addition to the PAH treatment
landscape and unmet therapeutic need. Gossamer management will
present along with the key PAH opinion leaders, Lewis Rubin, M.D.,
Emeritus Professor at UC San Diego School of Medicine, and Vallerie
McLaughlin, M.D., the Kim A. Eagle, M.D. Endowed Professor in
Cardiovascular Medicine at University of Michigan. As part of the
event, Gossamer Bio management, Dr. Rubin and Dr. McLaughlin will
be available for questions.
Lewis J. Rubin, M.D., is Professor of Medicine, Emeritus and
former Director of the Division of Pulmonary and Critical Care
Medicine at the University of California, San Diego School of
Medicine, and Adjunct Professor of Medicine at Columbia University
College of Physicians and Surgeons. He has published nearly 300
peer-reviewed scientific papers and seventy-five book chapters, and
he has edited seven books dealing with the pulmonary circulation.
He has been the Principal Investigator or a Steering Committee
member for the clinical trials leading to regulatory approval of
most currently approved medical therapies for PAH. He has served on
the editorial boards of the Annals of Internal Medicine and the
American Journal of Respiratory and Critical Care Medicine, and as
senior consulting editor for the Journal of the American College of
Cardiology and the Journal of Heart and Lung Transplantation. He
has served as an advisor to the NIH, the FDA, and numerous medical
and scientific organizations worldwide. He is a member of the Board
of Trustees of Yeshiva University. He is also a member of the
American Society of Clinical Investigation, and the recipient of
the Dickinson Richards Memorial Award from the American Heart
Association, the Simon Dack Award from the American College of
Cardiology, and the Lifetime Achievement Award from the Pulmonary
Vascular Research Institute. He was listed among Thomson Reuters’
Most Influential Researchers in the World in 2014 and 2015, and he
received the CHEST College Medalist Award from the American College
of CHEST Physicians in 2016. Most recently, Dr. Rubin was presented
with the European Respiratory Society’s ERS Award for Lifetime
Achievement in Pulmonary Arterial Hypertension.
Vallerie V. McLaughlin, M.D., is the Kim A. Eagle, M.D., Endowed
Professor of Cardiovascular Medicine, Associate Chief Clinical
Officer for Cardiovascular Services of the UMMG, Director of the
Pulmonary Hypertension (PH) Program, and Associate Chief of
Cardiovascular Medicine at the University of Michigan, Ann Arbor,
MI. She is a Fellow of the American College of Cardiology, the
American College of CHEST Physicians and the American Heart
Association, and she is a member of the American Thoracic Society.
She has served as Chair of the American Heart Association “Women in
Cardiology” Committee, Chair of the American College of
Cardiology/American Heart Association Clinical Expert Consensus
Document on PH, member of the American College of Cardiology
Scientific Sessions Program Committee, and member of the Scientific
Committee for the World Symposium on Pulmonary Hypertension 2008,
2013, and 2018. Professor McLaughlin is a past Chair of the
Scientific Leadership Council of the Pulmonary Hypertension
Association, past Editor-in-Chief of Advances in Pulmonary
Hypertension and past Chair of the Pulmonary Hypertension
Association Board of Trustees. She was inaugurated as a charter
member into the Clinical Excellence Society at the University of
Michigan and is a founding member of the World Symposia on
Pulmonary Hypertension Association.
Conference Call and Webcast
Gossamer will host a conference call and live audio webcast at
11:00 am ET on Tuesday, December 15. The live audio webcast may be
accessed through the “Events / Presentations” page in the
“Investors” section of the Company's website at
www.gossamerbio.com. Alternatively, the conference call may be
accessed through the following:
Conference ID: 6947845 Domestic Dial-in Number:
(833) 640-7726 International Dial-in Number: (602) 585-9912
Live Webcast:
https://edge.media-server.com/mmc/p/ztf8h6mc
A replay of the audio webcast will be available for 30 days on
the “Investors” section of the Company's website,
www.gossamerbio.com.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on discovering, acquiring, developing and commercializing
therapeutics in the disease areas of immunology, inflammation and
oncology. Its goal is to be an industry leader in each of these
therapeutic areas and to enhance and extend the lives of patients
suffering from such diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201207005241/en/
For Investors and Media: Bryan Giraudo, Chief Financial
Officer Gossamer Bio Investor Relations ir@gossamerbio.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Apr 2023 to Apr 2024